[go: up one dir, main page]

KR950010897A - 신규의 화학적 보호제(chemopreventive agent) 및 그의 제조방법 - Google Patents

신규의 화학적 보호제(chemopreventive agent) 및 그의 제조방법 Download PDF

Info

Publication number
KR950010897A
KR950010897A KR1019930021876A KR930021876A KR950010897A KR 950010897 A KR950010897 A KR 950010897A KR 1019930021876 A KR1019930021876 A KR 1019930021876A KR 930021876 A KR930021876 A KR 930021876A KR 950010897 A KR950010897 A KR 950010897A
Authority
KR
South Korea
Prior art keywords
hydrogen
methyl
phenyl
pyrazine
agent
Prior art date
Application number
KR1019930021876A
Other languages
English (en)
Other versions
KR0138005B1 (ko
Inventor
김낙두
이종욱
김상건
최영노
Original Assignee
김태훈
주식회사 유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김태훈, 주식회사 유한양행 filed Critical 김태훈
Priority to KR1019930021876A priority Critical patent/KR0138005B1/ko
Priority to EP94931210A priority patent/EP0674628B1/en
Priority to JP7511619A priority patent/JP2670384B2/ja
Priority to PCT/KR1994/000144 priority patent/WO1995011236A1/en
Priority to US08/454,160 priority patent/US5658913A/en
Priority to DE69422275T priority patent/DE69422275T2/de
Priority to CN94190810A priority patent/CN1043887C/zh
Publication of KR950010897A publication Critical patent/KR950010897A/ko
Application granted granted Critical
Publication of KR0138005B1 publication Critical patent/KR0138005B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)로 표시되는 신규의 화학적 보호제 (Chemopreventive agent) 및 그의 제조방법에 관한 것으로, 더 상세하게는 체내대사에 있어서 제1상 반응은 억제시키고, 제2상 반응은 증가시키는 작용을 함으로써, 화학적 보호제(Chemopreyentiye agent)로 작용가능한 피라진 유도체 및 그의 제조방법에 관한 것이다.
여기서, R1은 수소 또는 C1-3알킬이고, R2는 페닐, 푸란일(furanyl), 또는 -C(Ra)=C(Rb)(Rc)이고, R2가 -C(Ra)=C(Rb) (Rc)일때, Ra, Rb, 및 Rc는 같거나 다를 수 있으며, 수소, 메틸, 또는 페닐이다.

Description

신규의 화학적 보호제(Chemopreventive agent)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 파라진과 본 발명의 화합물 투여시 웨스턴 블럿(Western blot)결과 (제1상효소)를 나타낸 도면이고,
제2도는 피라진과 본 발명의 화합물 투여시 p-니트로페놀 하이드를라제의 활성도변화를 나타낸 도면이고,
제3도는 피라진과 본 발명의 화합물 투여시 아닐린 하이드록실라제의 활성도 변화를 나타낸 도면이고,
제4도는 피라진과 본 발명의 화할물 투여시 N-니트로디메틸아민디메틸라제의 활성도 변화를 나타낸 도면이고,
제5도는 이소니아지드(INAH)와 본 발명의 화합물 투여시 웨스턴 블럿 (Western blot) 결과를 나타낸 도면이고,
제6도는 피라진과 본 발명의 화합물 투여시 웨스턴 블럿(Western blot) 결과(제2상요소)를 나타낸 도면이고,
제7도는 본 발명의 화합물 투여시 GST의 활성도변화를 나타낸 도면이다

Claims (5)

  1. 하기 일반식(Ⅰ)로 표시되는 것을 특징으로 하는 화학적 보호제(Chemopreventive agent).
    여기서, R1은 수소 또는 C1-3알킬이고, R2는 페닐, 푸란일(furanyl), 또는 -C(Ra)=C(Rb) (Rc)이고, R가 -C(Ra)=C(Rb) (Rc)일때, Ra, Rb, 및 Rc는 같거나 다를 수 있으며, 수소, 메틸, 또는 페닐이다.
  2. 제1항에 있어서, R1이 수소 또는 메틸이고, R2가 -C(Ra)=C(Rb) (Rc)이며, Ra는 수소이고, Rb및 Rc는 수소 또는 메틸인 것을 특징으로 하는 화학적 보호제(Chemopreventive agent).
  3. 제1항에 있어서, (2-프로펜-1-티오)피라진, 벤질티오피라진, (3-메틸-2-부펜-1-티오)피라진, 신나밀티오피라진, 퓨르프릴티오피라진, (3-메틸-3-부텐-1-티오)피라진, (2-부텐-1-티오)피라진, (3-부텐-2-티오)피라진으로 구성된 군으로부터 선택된 것을 특징으로 하는 화학적 보호제(Chemopreventive agent).
  4. 일반식(Ⅱ)로 표시되는 화합물과 일반식(Ⅲ)로 표시되는 화합물을 반응시키는 것을 특징으로 하는 일반식(Ⅰ)로 표시되는 화학적 보호제(Chemopreventive agent)의 제조방법.
    여기서 X는 할로겐 또는 히드록시를 나타내며, R1은 수소 또는 C1-3알킬이고, R2는 페닐, 푸란일(furanyl), 또는 -C(Ra)=C(Rb) (Rc)이고, R2가 -C(Ra)=C(Rb) (Rc)일때, Ra, Rb, 및 Rc는 같거나 다를 수 있으며, 수소, 메틸, 또는 페닐이다.
  5. 하기 일반식(Ⅰ)로 표시되는 화합물 및 약제학적으로 허용가능한 담체를 함유하는 화학적 보호제(Chemopreventive agent)조성물
    여기서 R1은 수소 또는 C1-3알킬이고, R2는 페닐, 푸란일(furanyl), 또는 -C(Ra)=C(Rb) (Rc)이고, R2가 -C(Ra)=C(Rb) (Rc)일때, Ra, Rb, 및 Rc는 같거나 다를 수 있으며, 수소, 메틸, 또는 페닐이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930021876A 1993-10-21 1993-10-21 신규의 화학적 보호제(chemopreventive agent)및 그의 제조방법 KR0138005B1 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1019930021876A KR0138005B1 (ko) 1993-10-21 1993-10-21 신규의 화학적 보호제(chemopreventive agent)및 그의 제조방법
EP94931210A EP0674628B1 (en) 1993-10-21 1994-10-21 Chemopreventive compounds and a preparation method and use thereof
JP7511619A JP2670384B2 (ja) 1993-10-21 1994-10-21 新規化学的保護化合物ならびにその調製法及び用途
PCT/KR1994/000144 WO1995011236A1 (en) 1993-10-21 1994-10-21 New chemopreventive compounds and a preparation method and use thereof
US08/454,160 US5658913A (en) 1993-10-21 1994-10-21 Chemopreventive compounds and a preparation method and use thereof
DE69422275T DE69422275T2 (de) 1993-10-21 1994-10-21 Chemopräventive verbindungen, verfahren zur herstellung und anwendungen
CN94190810A CN1043887C (zh) 1993-10-21 1994-10-21 抗化学活性的化合物及其制备方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930021876A KR0138005B1 (ko) 1993-10-21 1993-10-21 신규의 화학적 보호제(chemopreventive agent)및 그의 제조방법

Publications (2)

Publication Number Publication Date
KR950010897A true KR950010897A (ko) 1995-05-15
KR0138005B1 KR0138005B1 (ko) 1998-05-15

Family

ID=19366274

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930021876A KR0138005B1 (ko) 1993-10-21 1993-10-21 신규의 화학적 보호제(chemopreventive agent)및 그의 제조방법

Country Status (7)

Country Link
US (1) US5658913A (ko)
EP (1) EP0674628B1 (ko)
JP (1) JP2670384B2 (ko)
KR (1) KR0138005B1 (ko)
CN (1) CN1043887C (ko)
DE (1) DE69422275T2 (ko)
WO (1) WO1995011236A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0157105B1 (ko) * 1995-10-14 1998-11-16 김태훈 화학적 발암억제제
EP2000532A1 (en) * 1999-08-05 2008-12-10 Merck & Co., Inc. Methods of measuring human cytochrome P450 (CYP2C8/9)
US7078045B2 (en) * 2000-03-02 2006-07-18 Sang-Geon Kim Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
GB0008689D0 (en) * 2000-04-07 2000-05-31 Nokia Networks Oy A method and system for processing signals
JP2003530353A (ja) * 2000-04-07 2003-10-14 キム，サン，ギョン オルチプラズの肝繊維化及び肝硬変症進行の予防及び治療剤としての使用方法、及びオルチプラズを主成分として含有する製薬組成物
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
US7001619B2 (en) * 2002-03-27 2006-02-21 Council Of Scientific And Industrial Research Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs
US7498331B2 (en) * 2003-11-06 2009-03-03 United States Of America As Represented By The Secretary Of The Army Arthropod repellent pharmacophore models, compounds identified as fitting the pharmacophore models, and methods of making and using thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931166A (en) * 1972-04-13 1976-01-06 Firmenich & Cie Certain 2,5-dimethyl-3-thiopyrazines
CA1001631A (en) * 1972-05-05 1976-12-14 Merck Sharp And Dohme (I.A.) Corp. 2-(3-substituted amino-2-hydroxy-propoxy)-3-substituted pyrazines and method for preparation
US4085109A (en) * 1974-06-24 1978-04-18 Firmenich & Cie Pyridine sulfur flavoring agents
US3989713A (en) * 1974-07-24 1976-11-02 Firmenich & Cie Pyrrylmethylthio flavoring agents
GB1549829A (en) * 1976-05-26 1979-08-08 Farmaceutici Italia 10'-methoxy-1',6'-dimethylergoline-8'-beta-methyl-amino(or thio)-pyrazines

Also Published As

Publication number Publication date
US5658913A (en) 1997-08-19
EP0674628B1 (en) 1999-12-22
JPH08503972A (ja) 1996-04-30
CN1115981A (zh) 1996-01-31
JP2670384B2 (ja) 1997-10-29
DE69422275T2 (de) 2000-08-10
EP0674628A1 (en) 1995-10-04
CN1043887C (zh) 1999-06-30
DE69422275D1 (de) 2000-01-27
KR0138005B1 (ko) 1998-05-15
WO1995011236A1 (en) 1995-04-27

Similar Documents

Publication Publication Date Title
KR850003890A (ko) 1H-이미다조[4,5c]-퀴놀린-4-아민의 제조방법
KR890006599A (ko) 복소환 유도체, 그의 제법 및 이를 활성성분으로 함유하는 방사선 감응제 및 항비루스제
KR950000728A (ko) 포스포네이트 뉴클레오티드 에스테르 유도체
KR880001651A (ko) 이미다조 [4,5-b] 피리딘 유도체, 그의 제조방법 및 그를 함유하는 항궤양제
IE46167L (en) Alkaloid-containing nasal pharmaceutical compositions
AU3515497A (en) Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
EP0219876A3 (en) Antihypertensive agents comprising 2-alkynyladenosines as active ingredients
KR920700201A (ko) 신규 1α-히드록시비타민D 2 에피머 및 유도체
SE8700113D0 (sv) An oil-in-water pesticidal emulsion
AU552908B2 (en) 4 n-phenyl benzyl-aminomethyl-imidazole
KR960703586A (ko) 광감작제(Photosensitizers)
KR950010897A (ko) 신규의 화학적 보호제(chemopreventive agent) 및 그의 제조방법
CA2053820A1 (en) Method of Inhibiting Metabolism of Cholesterol
KR900018048A (ko) 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌
KR860008111A (ko) 인딘과 나프탈렌 유도체의 제조방법
KR970074773A (ko) 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2, 4-피리미딘디온 유도체 및 그의 제조 방법
KR910014380A (ko) 이미자조피리다진 화합물, 그의 제법 및 용도
KR880009926A (ko) 알킬멜라토닌
ES8701174A1 (es) Un metodo de preparacion de un compuesto de tiadiazina
KR850006176A (ko) (아릴티오) 피리딜 알칼올 유도체의 제조방법
KR880005079A (ko) 3-아미노카르보닐-1,4-디히드로피리딘-5-카르복실산 화합물, 그의 제조방법, 및 그를 함유하는 약학조성물
KR970074764A (ko) 불소화된 비타민 d₃ 동족체
AU579665B2 (en) 2-pyridine-thiol derivatives
KR850001188A (ko) 벤조푸란 유도체의 제조방법 및 조성물
MY102090A (en) Compounds with antiinflammatory activity, process for preparation thereof and pharmaceutical compositions therefrom

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19931021

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19931216

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950127

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19931021

Comment text: Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 19960510

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980123

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980214

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980214

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20011114